Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis

BACKGROUND: Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuda, Yoshinori, Omoto, Seitaro, Taniura, Takehito, Shouzu, Akira, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835142/
https://www.ncbi.nlm.nih.gov/pubmed/27110135
http://dx.doi.org/10.2147/IJGM.S102070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835142/
https://www.ncbi.nlm.nih.gov/pubmed/27110135
http://dx.doi.org/10.2147/IJGM.S102070

Ejemplares similares